Current management of refractory ascites in patients with cirrhosis

Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%–10% of all patients with ascites due to cirrhosis. Refractory ascites leads to a poor quality of life and high mortality rate. Ascites develops as a result of portal hypertension, which leads to water–sodium retention and renal failure. Various therapeutic measures can be used for refractory ascites, including large-volume paracentesis, transjugular intrahepatic portosystemic shunt, vasoconstrictive drugs, and an automated low-flow ascites pump system. However, ascites generally can be resolved only by liver transplantation. Because not all patients can undergo liver transplantation, traditional approaches are still used to treat refractory ascites. The choice of treatment modality for refractory ascites depends, among other factors, on the condition of the patient.

• Publication year

  2017

• Venue

  Journal of International Medical Research

• Publication date

  2017-12-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0300060517735231PMID 29210304PMCID 5972247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.

  2017cited by this paper
• Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.

  2017cited by this paper
• Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites

  2017cited by this paper
• Transjugular Intrahepatic Portosystemic Shunts in Patients with Cirrhosis with Refractory Ascites: Comparison of Clinical Outcomes by Using 8- and 10-mm PTFE-covered Stents.

  2017influential reference
• Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis.

  2016cited by this paper
• Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.

  2016cited by this paper
• Acute on Chronic Liver Failure Secondary to Drugs: Causes, Outcome and Predictors of Mortality

  2016cited by this paper
• Automated low flow pump system for the treatment of refractory ascites: a single-center experience

  2015cited by this paper
• The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials

  2015cited by this paper
• Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.

  2015cited by this paper
• Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.

  2014cited by this paper
• Pre‐transjugular intrahepatic portosystemic shunts (TIPS) prediction of post‐TIPS overt hepatic encephalopathy: The Critical Flicker Frequency is more accurate than psychometric tests

  2014cited by this paper
• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012

  2013cited by this paper
• Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study

  2013cited by this paper
• TIPS: 25 years later.

  2013cited by this paper
• A new method for therapeutic paracentesis: the automated low flow pump system. Comments in the context of the history of paracentesis.

  2013cited by this paper
• Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study.

  2013cited by this paper
• Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials

  2012cited by this paper
• Tolvaptan in patients with autosomal dominant polycystic kidney disease.

  2012cited by this paper
• Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review

  2011cited by this paper
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

  2010cited by this paper
• Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial

  2010cited by this paper
• TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update

  2010cited by this paper
• Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial

  2010cited by this paper
• Management of adult patients with ascites due to cirrhosis: An update

  2009cited by this paper
• Evaluation and management of patients with refractory ascites.

  2009cited by this paper
• Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study.

  2009cited by this paper
• Bacterial infections, sepsis, and multiorgan failure in cirrhosis.

  2008cited by this paper
• Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.

  2004cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2004cited by this paper
• Management of cirrhosis and ascites.

  2004cited by this paper
• Treatment of Refractory Ascites Using Transjugular Intrahepatic Portosystemic Shunt (TIPS) (A Caution)

  2004cited by this paper
• Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE‐covered stentgrafts versus bare stents

  2003cited by this paper
• Treatment of symptomatic hyponatremia.

  2003cited by this paper
• The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club

  2003influential reference
• Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.

  2003cited by this paper
• Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.

  2003cited by this paper
• The North American Study for the Treatment of Refractory Ascites.

  2003cited by this paper
• A model to predict survival in patients with end‐stage liver disease

  2001cited by this paper
• A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES

  2000cited by this paper
• A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.

  2000cited by this paper
• Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites

  1998cited by this paper
• Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.

  1998cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

  1996cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis

  1996cited by this paper
• Management of Ascites and Renal Failure in Cirrhosis

  1994cited by this paper
• Partial Versus Total Portacaval Shunt in Alcoholic Cirrhosis Results of a Prospective, Randomized Clinical Trial

  1994cited by this paper
• Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study

  1994cited by this paper
• The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites

  1992cited by this paper
• Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

  1988cited by this paper
• Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.

  1987cited by this paper
• Compensated cirrhosis: Natural history and prognostic factors

  1987cited by this paper
• The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients).

  1986cited by this paper
• Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites.

  1985cited by this paper

• Prognostic determinants and mortality risk of advanced schistosomiasis revealed by Lasso-Cox regression integrative approach

  2026cites this paper
• Integrated analysis of gut microbiota structure and metabolic function in patients with cirrhosis and refractory ascites

  2026cites this paper
• Future research direction of portal hypertension based on Baveno VII

  2025cites this paper
• Advancements in ascites management: a comprehensive narrative review of the Alfa Pump system

  2024cites this paper
• Assessment of Albumin Usage Patterns and Appropriateness in a Comprehensive Cancer Centre

  2024cites this paper
• Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan

  2023cites this paper
• A soft, bioinspired artificial lymphatic system for interactive ascites transfer

  2023cites this paper
• Intravascular Ultrasound for Transjugular Intrahepatic Portosystemic Shunt Creation: “TIPS” and Tricks

  2023cites this paper
• A Nomogram for Predicting Prognosis of Advanced Schistosomiasis japonica in Dongzhi County—A Case Study

  2023cites this paper
• Efficacy and Safety of Ascites Treatment in Liver Cirrhosis

  2022cites this paper
• Current treatment options of refractory ascites in liver cirrhosis - A systematic review and meta-analysis.

  2022cites this paper
• Refractory ascites of complex genesis in patients with a severe combined form of extrahepatic portal hypertension

  2022cites this paper
• Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites

  2022cites this paper
• Comparison of Low Dose Albumin Versus Full Dose Albumin in Improving Refractory Ascites in Cirrhotic Patients

  2022cites this paper
• Kosteneffizienz der Behandlung von Aszites bei Leberzirrhose im Rahmen des G-DRG-Systems

  2022influential citation
• Prevalence of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis with Ascites

  2022cites this paper
• Preventive and Treatment Interventions for Abdominal Ascites of Patients with Liver Cirrhosis: A Systematic Review of Randomized Controlled Trials

  2021cites this paper
• Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis

  2020cites this paper
• Current Management of Refractory Ascites in Hepatoma: A Case Report

  2020cites this paper
• Exploring a New Management Option for Patients With Refractory Ascites: The PeriLeve Device

  2020cites this paper
• Refractory Chylous Ascites with Chylothorax and an Umbilical Hernia in a Patient Ineligible for a Transjugular Intrahepatic Portosystemic Shunt

  2020cites this paper
• Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications

  2020cites this paper
• Refractory Ascites in Patient with Liver Cirrhosis: A Case Report

  2020cites this paper
• Use of Peritoneal Catheters for Patients Receiving Palliative Care

  2020cites this paper
• Refractory ascites—the contemporary view on pathogenesis and therapy

  2019cites this paper
• Impact of Vaptans on Clinical Outcomes in Cirrhosis Patients: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature

  2018cites this paper
• World Journal of Hepatology

  year unknowncites this paper